ROCKWELL MEDICAL, INC. (RMTI) - Dilution Analysis

10-Q filing | 39.4M shares outstanding

10-K filing | 36.0M shares outstanding

10-Q filing | 36.0M shares outstanding

10-Q filing | 34.3M shares outstanding

10-Q filing | 34.1M shares outstanding

10-K filing | 31.1M shares outstanding

10-Q filing | 32.4M shares outstanding

S-3 filing: Rockwell Medical, Inc. is registering to offer up to $100,000,000 in aggregate principal amount of its common stock, preferred stock, debt securities, warrants and/or units from time to time.

10-Q filing | 30.5M shares outstanding

10-Q filing | 29.3M shares outstanding

10-K filing | 29.3M shares outstanding

8-K filing: Rockwell Medical entered into an amended loan agreement with Innovatus and issued a warrant to purchase 191,096 shares of common stock at an exercise price of $1.83 per share on January 2, 2024.

10-Q filing | 27.5M shares outstanding

S-3 filing: Resale of 3,750,000 shares of common stock issuable upon the exercise of warrants with an exercise price of $5.13 per share by the selling stockholder.

10-Q filing | 28.5M shares outstanding

10-Q filing | 13.7M shares outstanding

10-K filing | 12.6M shares outstanding

10-Q filing | 10.5M shares outstanding

10-Q filing | 10.7M shares outstanding

S-3 filing: Resale of 1,404,956 shares of common stock by a selling stockholder, representing shares issuable upon conversion of Series X Preferred Stock.

S-1 filing: The selling stockholder is offering on a resale basis an aggregate of 11,168,667 shares of common stock, including shares issuable upon the exercise of 9,900,990 outstanding warrants with a per share exercise price equal to $1.39 and 1,267,897 outstanding pre-funded warrants with a per share exercise price equal to $0.0001.

8-K filing: Rockwell Medical, Inc. issued an additional 7,500 shares of Series X Convertible Preferred Stock to DaVita Inc. for gross proceeds of $7,500,000 on June 16, 2022, following the achievement of a capital raise milestone. ($7.5M proceeds)

8-K filing: Rockwell Medical, Inc. completed a registered direct offering of 844,613 shares of common stock at $1.39 per share and pre-funded warrants, and a concurrent private placement of warrants and pre-funded warrants, with net proceeds of approximately $14.9 million.

10-Q filing | 8.5M shares outstanding

8-K filing: Rockwell Medical, Inc. entered into a Securities Purchase Agreement with DaVita Inc. on April 6, 2022, to issue up to $15 million of Series X Convertible Preferred Stock, with an initial issuance of 7,500 shares for gross proceeds of $7,500,000. ($7.5M proceeds)

10-K filing | 93.8M shares outstanding

10-Q filing | 93.9M shares outstanding

S-3 filing: Rockwell Medical, Inc. may issue up to $200,000,000 of common stock, preferred stock, debt securities, warrants and/or units from time to time.

10-Q filing | 93.7M shares outstanding

10-Q filing | 93.6M shares outstanding

10-K filing | 93.6M shares outstanding

10-Q filing | 93.6M shares outstanding

8-K filing: Rockwell Medical, Inc. entered into a Securities Purchase Agreement to issue and sell 21,818,544 shares of common stock and warrants to purchase up to 23,178,809 shares, along with pre-funded warrants for 1,360,265 shares, in a registered direct offering, resulting in gross proceeds of approximately $35.0 million. ($35.0M proceeds)

10-Q filing | 65.4M shares outstanding

10-Q filing | 69.1M shares outstanding

10-K filing | 69.0M shares outstanding

8-K filing: Rockwell Medical, Inc. closed the over-allotment option exercise on February 21, 2020, issuing 478,723 shares of common stock to the underwriter.

8-K filing: Rockwell Medical, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to issue and sell 3,191,489 shares of common stock at a price of $2.22 per share, with an option for the underwriter to purchase an additional 478,723 shares, which closed on February 6, 2020.